EXG-34217 is under clinical development by Elixirgen Therapeutics and currently in Phase I for Bone Disorders. According to GlobalData, Phase I drugs for Bone Disorders have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EXG-34217’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EXG-34217 overview
EXG-34217 is under development for the treatment of inherited bone marrow failure syndromes (IBMFS) including telomere biology disorders, dyskeratosis congenita, aplastic anemia and myelodysplastic syndrome. The therapeutic candidate constitutes stem cells transfected with ZSCAN4 gene encoding vectors. It is administered through parenteral route.
It was also under development for the treatment of Fanconi anemia
Elixirgen Therapeutics overview
Elixirgen Therapeutics (Elixirgen) is a biotechnology company that focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines. Elixirgen is headquartered in Baltimore, Maryland, the US.
For a complete picture of EXG-34217’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
